Director: Hermitage Museum Hosts over 4.5 Million Tourists Annually

The State Hermitage Museum is seen illuminated in red for the centenary of the Bolshevik revolution in Saint Petersburg on October 25, 2017. AFP
The State Hermitage Museum is seen illuminated in red for the centenary of the Bolshevik revolution in Saint Petersburg on October 25, 2017. AFP
TT

Director: Hermitage Museum Hosts over 4.5 Million Tourists Annually

The State Hermitage Museum is seen illuminated in red for the centenary of the Bolshevik revolution in Saint Petersburg on October 25, 2017. AFP
The State Hermitage Museum is seen illuminated in red for the centenary of the Bolshevik revolution in Saint Petersburg on October 25, 2017. AFP

More than 4.5 million people visit the Hermitage Museum a year, confirmed the director of the museum and the Russian Orientalist Mikhail Piotrovsky during an interview with Tass agency.

He said that this huge turnout is a "big and serious problem" that faces most of the world's major museums, including Hermitage, which accommodates thousands of visitors.

Piotrovsky said that the museum's main building can host up to 7,111 visitors, and stressed the importance of maintaining safety and security procedures during the reception of ministers.

"The ability of the Hermitage to contain this number of visitors does not mean that it can welcome them at once. Instead, we must allow the entry of the number of visitors whose exit from the museum we can secure in 10 minutes, in case a fire breaks out."

The Hermitage director said that during an international conference in the Vatican, directors of international museums discussed the protection of cities and museums from tourist flows, pointing out that "the Hermitage tackled this problem 40 years ago, when the number of visitors, was like now, about 4.5 million per year."

Piotrovsky explained that such numbers require the protection of cultural facilities without affecting the work and reception of visitors. He also saw that "the problem is twofold: the first is how to protect historic buildings, and the second is how to make museums available to anyone who wants to visit," highlighting that the museums' accommodation ability is limited and that "visitors have to recognize that the museum is like the theater."

To address this problem, museum directors participating in the Vatican International Conference formulated a set of recommendations for museum managements, including practical suggestions such as designing virtual versions featuring all museum exhibits to allow people to see them before visiting the museum.

According to the Hermitage director, the conference participants are working on developing joint international evaluation standards. The Russian orientalist said there is only one rating mechanism for museums dubbed the "Notre Dame rating" and that "the Hermitage is the fourth on Notre Dame's list."

He confirmed that his museum is currently cooperating with the Erasmus University Rotterdam to set global standards to be adopted by experts in the museums rating worldwide. He explained that based on the scientific standards of those lists, the St. Petersburg's Hermitage is always among the top ten museums in the world.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”